{'fraction_non_alphanumeric': 0.019622641509433963, 'fraction_numerical': 0.00830188679245283, 'mean_word_length': 4.919642857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Re-treatment with interferon-alpha in chronic hepatitis B and C virus infection].

The efficacy of interferon-alpha retreatment was assessed in patients with chronic hepatitis B or C, not responding to a first cycle of interferon or reactivating thereafter. 27 patients with chronic hepatitis B and 25 patients with chronic hepatitis C were investigated. After an interval of at least 6 months these patients received an interferon-alpha retreatment in a higher dosage schedule and with a different interferon-alpha subtype. In patients with chronic hepatitis B a loss of serum HBV-DNA was observed in 59% patients after interferon-alpha retreatment. HBeAg seroconversion occurred in 8 of these patients. In chronic hepatitis C 32% of the patients responded completely to the second cycle of interferon-alpha treatment with a normalization of ALT associated with a loss of serum HCV-RNA. A partial response with a marked reduction of ALT was seen in 4 patients. In chronic hepatitis B and C a complete or partial response to the retreatment was closely associated with the response status after the first cycle. Thus, interferon retreatment seems to be effective in patients with chronic hepatitis B or C, especially in the subgroup of patients exhibiting a partial or complete response after the first interferon treatment.